{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:02:36Z","timestamp":1793120556468,"version":"4.5.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T00:00:00Z","timestamp":1566518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T00:00:00Z","timestamp":1566518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), also\nknown as APO2L, belongs to the tumor necrosis factor family. By binding to the death\nreceptor 4 (DR4) or DR5, TRAIL induces apoptosis of tumor cells without causing side\ntoxicity in normal tissues. In recent years TRAIL-based therapy has attracted great\nattention for its promise of serving as a cancer drug candidate. However, the\ntreatment efficacy of TRAIL protein was under expectation in the clinical trials\nbecause of the short half-life and the resistance of cancer cells. TRAIL gene\ntransfection can produce a \u201cbystander effect\u201d of tumor cell killing and provide a\npotential solution to TRAIL-based cancer therapy. In this review we focus on TRAIL\ngene therapy and various design strategies of TRAIL DNA delivery including non-viral\nvectors and cell-based TRAIL therapy. In order to sensitize the tumor cells to\nTRAIL-induced apoptosis, combination therapy of TRAIL DNA with other drugs by the\ncodelivery methods for yielding a synergistic antitumor efficacy is summarized. The\nopportunities and challenges of TRAIL-based gene delivery and therapy are\ndiscussed.<\/jats:p>","DOI":"10.1038\/s41401-019-0287-8","type":"journal-article","created":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T09:09:14Z","timestamp":1566551354000},"page":"1373-1385","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["TRAIL-based gene delivery and therapeutic\nstrategies"],"prefix":"10.1038","volume":"40","author":[{"given":"Hui-hai","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-zhuo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,23]]},"reference":[{"key":"287_CR1","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt.3802","volume":"35","author":"SF Dowdy","year":"2017","unstructured":"Dowdy SF. Overcoming cellular barriers for RNA therapeutics. Nat\nBiotechnol. 2017;35:222\u20139.","journal-title":"Nat Biotechnol"},{"key":"287_CR2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1006\/excr.2000.4840","volume":"256","author":"H Walczak","year":"2000","unstructured":"Walczak H, Krammer PH. The CD95 (APO-1\/Fas) and the TRAIL (APO-2L)\napoptosis systems. Exp Cell Res. 2000;256:58\u201366.","journal-title":"Exp Cell Res"},{"key":"287_CR3","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1164\/ajrccm\/138.6.1377","volume":"138","author":"KJ Tracey","year":"1988","unstructured":"Tracey KJ, Lowry SF, Cerami A. Cachetin\/TNF-alpha in septic shock\nand septic adult respiratory distress syndrome. Am Rev Respir Dis.\n1988;138:1377\u20139.","journal-title":"Am Rev Respir Dis"},{"key":"287_CR4","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/364806a0","volume":"364","author":"J Ogasawara","year":"1993","unstructured":"Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T,\nKitamura Y, et al. Lethal effect of the anti-Fas antibody in mice. Nature.\n1993;364:806\u20139.","journal-title":"Nature"},{"key":"287_CR5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","volume":"3","author":"SR Wiley","year":"1995","unstructured":"Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et\nal. Identification and characterization of a new member of the TNF family that\ninduces apoptosis. Immunity. 1995;3:673\u201382.","journal-title":"Immunity"},{"key":"287_CR6","doi-asserted-by":"crossref","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","volume":"271","author":"RM Pitti","year":"1996","unstructured":"Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A.\nInduction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis\nfactor cytokine family. J Biol Chem. 1996;271:12687\u201390.","journal-title":"J Biol Chem"},{"key":"287_CR7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrc.2017.28","volume":"17","author":"S von Karstedt","year":"2017","unstructured":"von Karstedt S, Montinaro A, Walczak H. Exploring the TRAILs less\ntravelled: TRAIL in cancer biology and therapy. Nat Rev Cancer.\n2017;17:352\u201366.","journal-title":"Nat Rev Cancer"},{"key":"287_CR8","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/jmv.20938","volume":"79","author":"D Gibellini","year":"2007","unstructured":"Gibellini D, Borderi M, De Crignis E, Cicola R, Vescini F,\nCaudarella R, et al. RANKL\/OPG\/TRAIL plasma levels and bone mass loss evaluation\nin antiretroviral naive HIV-1-positive men. J Med Virol.\n2007;79:1446\u201354.","journal-title":"J Med Virol"},{"key":"287_CR9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ccr.2014.04.028","volume":"26","author":"JD Graves","year":"2014","unstructured":"Graves JD, Kordich JJ, Huang TH, Piasecki J, Bush TL, Sullivan T,\net al. Apo2L\/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate\nto promote receptor clustering and antitumor activity. Cancer Cell.\n2014;26:177\u201389.","journal-title":"Cancer Cell"},{"key":"287_CR10","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1517\/14728222.2015.1049838","volume":"19","author":"B Lim","year":"2015","unstructured":"Lim B, Allen JE, Prabhu VV, Talekar MK, Finnberg NK, El-Deiry WS.\nTargeting TRAIL in the treatment of cancer: new developments. Expert Opin Ther\nTargets. 2015;19:1171\u201385.","journal-title":"Expert Opin Ther Targets"},{"key":"287_CR11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/5517","volume":"5","author":"H Walczak","year":"1999","unstructured":"Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et\nal. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing\nligand in vivo. Nat Med. 1999;5:157\u201363.","journal-title":"Nat Med"},{"key":"287_CR12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","volume":"104","author":"A Ashkenazi","year":"1999","unstructured":"Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et\nal. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin\nInvest. 1999;104:155\u201362.","journal-title":"J Clin Invest"},{"key":"287_CR13","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/80436","volume":"6","author":"B Halliwell","year":"2000","unstructured":"Halliwell B. A super way to kill cancer cells? Nat Med.\n2000;6:1105\u20136.","journal-title":"Nat Med"},{"key":"287_CR14","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J","volume":"73","author":"JFR Kerr","year":"1994","unstructured":"Kerr JFR, Winterford CM, Harmon BV. Apoptosis-its significance in\ncancer and cancer-therapy. Cancer. 1994;73:2013\u201326.","journal-title":"Cancer"},{"key":"287_CR15","doi-asserted-by":"crossref","first-page":"F21","DOI":"10.1084\/jem.192.8.F21","volume":"192","author":"S Roy","year":"2000","unstructured":"Roy S, Nicholson DW. Cross-talk in cell death signaling. J Exp Med.\n2000;192:F21\u20135.","journal-title":"J Exp Med"},{"key":"287_CR16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ccr.2012.05.014","volume":"22","author":"NS Wilson","year":"2012","unstructured":"Wilson NS, Yang A, Yang B, Couto S, Stern H, Gogineni A, et al.\nProapoptotic activation of death receptor 5 on tumor endothelial cells disrupts\nthe vasculature and reduces tumor growth. Cancer Cell.\n2012;22:80\u201390.","journal-title":"Cancer Cell"},{"key":"287_CR17","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.277.5327.815","volume":"277","author":"G Pan","year":"1997","unstructured":"Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy\nreceptor and a death domain-containing receptor for TRAIL. Science.\n1997;277:815\u20138.","journal-title":"Science"},{"key":"287_CR18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/science.276.5309.111","volume":"276","author":"G Pan","year":"1997","unstructured":"Pan G, O\u2019Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, et al.\nThe receptor for the cytotoxic ligand TRAIL. Science.\n1997;276:111\u20133.","journal-title":"Science"},{"key":"287_CR19","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.277.5327.818","volume":"277","author":"JP Sheridan","year":"1997","unstructured":"Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin\nD, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy\nreceptors. Science. 1997;277:818\u201321.","journal-title":"Science"},{"key":"287_CR20","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.1093\/emboj\/16.17.5386","volume":"16","author":"H Walczak","year":"1997","unstructured":"Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY,\nBoiani N, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO\nJ. 1997;16:5386\u201397.","journal-title":"EMBO J"},{"key":"287_CR21","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1084\/jem.186.7.1165","volume":"186","author":"MA Degli-Esposti","year":"1997","unstructured":"Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose\nRF, et al. Cloning and characterization of TRAIL-R3, a novel member of the\nemerging TRAIL receptor family. J Exp Med. 1997;186:1165\u201370.","journal-title":"J Exp Med"},{"key":"287_CR22","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1074-7613(00)80399-4","volume":"7","author":"MA Degli-Esposti","year":"1997","unstructured":"Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA,\nGoodwin RG. The novel receptor TRAIL-R4 induces NF-kappaB and protects against\nTRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity.\n1997;7:813\u201320.","journal-title":"Immunity"},{"key":"287_CR23","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S0960-9822(06)00422-2","volume":"7","author":"SA Marsters","year":"1997","unstructured":"Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D,\net al. A novel receptor for Apo2L\/TRAIL contains a truncated death domain. Curr\nBiol. 1997;7:1003\u20136.","journal-title":"Curr Biol"},{"key":"287_CR24","doi-asserted-by":"crossref","first-page":"23319","DOI":"10.1074\/jbc.M910438199","volume":"275","author":"A Truneh","year":"2000","unstructured":"Truneh A, Sharma S, Silverman C, Khandekar S, Reddy MP, Deen KC, et\nal. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5\nis the highest affinity receptor. J Biol Chem.\n2000;275:23319\u201325.","journal-title":"J Biol Chem"},{"key":"287_CR25","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.pharmthera.2013.06.009","volume":"140","author":"T Sessler","year":"2013","unstructured":"Sessler T, Healy S, Samali A, Szegezdi E. Structural determinants\nof DISC function: new insights into death receptor-mediated apoptosis\nsignalling. Pharmacol Ther. 2013;140:186\u201399.","journal-title":"Pharm Ther"},{"key":"287_CR26","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/cdd.2014.81","volume":"21","author":"J Lemke","year":"2014","unstructured":"Lemke J, von Karstedt S, Zinngrebe J, Walczak H. Getting TRAIL back\non track for cancer therapy. Cell Death Differ.\n2014;21:1350\u201364.","journal-title":"Cell Death Differ"},{"key":"287_CR27","first-page":"31","volume":"299","author":"SK Kelley","year":"2001","unstructured":"Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, et\nal. Preclinical studies to predict the disposition of Apo2L\/tumor necrosis\nfactor-related apoptosis-inducing ligand in humans: characterization of in vivo\nefficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther.\n2001;299:31\u20138.","journal-title":"J Pharm Exp Ther"},{"key":"287_CR28","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00280-015-2712-0","volume":"75","author":"KP Papadopoulos","year":"2015","unstructured":"Papadopoulos KP, Isaacs R, Bilic S, Kentsch K, Huet HA, Hofmann M,\net al. Unexpected hepatotoxicity in a phase I study of TAS266, a novel\ntetravalent agonistic Nanobody(R) targeting the DR5 receptor. Cancer Chemother\nPharmacol. 2015;75:887\u201395.","journal-title":"Cancer Chemother Pharmacol"},{"key":"287_CR29","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.2009.25.1991","volume":"28","author":"RS Herbst","year":"2010","unstructured":"Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O\u2019Dwyer PJ,\nGordon MS, et al. Phase I dose-escalation study of recombinant human\nApo2L\/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced\ncancer. J Clin Oncol. 2010;28:2839\u201346.","journal-title":"J Clin Oncol"},{"key":"287_CR30","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.2009.25.4847","volume":"28","author":"JC Soria","year":"2010","unstructured":"Soria JC, Smit E, Khayat D, Besse B, Yang X, Hsu CP, et al. Phase\n1b study of dulanermin (recombinant human Apo2L\/TRAIL) in combination with\npaclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous\nnon-small-cell lung cancer. J Clin Oncol. 2010;28:1527\u201333.","journal-title":"J Clin Oncol"},{"key":"287_CR31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fonc.2015.00069","volume":"5","author":"R Trivedi","year":"2015","unstructured":"Trivedi R, Mishra DP. Trailing TRAIL resistance: novel targets for\nTRAIL sensitization in cancer cells. Front Oncol. 2015;5:69.","journal-title":"Front Oncol"},{"key":"287_CR32","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1038\/sj.onc.1207232","volume":"22","author":"S Wang","year":"2003","unstructured":"Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family\ndeath receptors. Oncogene. 2003;22:8628\u201333.","journal-title":"Oncogene"},{"key":"287_CR33","doi-asserted-by":"crossref","first-page":"13879","DOI":"10.1039\/C7NR04959E","volume":"9","author":"X Wu","year":"2017","unstructured":"Wu X, Wang S, Li M, Wang A, Zhou Y, Li P, et al. Nanocarriers for\nTRAIL delivery: driving TRAIL back on track for cancer therapy. Nanoscale.\n2017;9:13879\u2013904.","journal-title":"Nanoscale"},{"key":"287_CR34","first-page":"3330","volume":"61","author":"S Kagawa","year":"2001","unstructured":"Kagawa S, He C, Gu J, Koch P, Rha SJ, Roth JA, et al. Antitumor\nactivity and bystander effects of the tumor necrosis factor-related\napoptosis-inducing ligand (TRAIL) gene. Cancer Res.\n2001;61:3330\u20138.","journal-title":"Cancer Res"},{"key":"287_CR35","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nature08402","volume":"461","author":"OR LA","year":"2009","unstructured":"LA OR, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD, et al.\nMembrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature.\n2009;461:659\u201363.","journal-title":"Nature"},{"key":"287_CR36","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1021\/mp300258c","volume":"10","author":"D De Miguel","year":"2013","unstructured":"De Miguel D, Basanez G, Sanchez D, Malo PG, Marzo I, Larrad L, et\nal. Liposomes decorated with Apo2L\/TRAIL overcome chemoresistance of human\nhematologic tumor cells. Mol Pharmacol. 2013;10:893\u2013904.","journal-title":"Mol Pharm"},{"key":"287_CR37","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nmat1645","volume":"5","author":"D Putnam","year":"2006","unstructured":"Putnam D. Polymers for gene delivery across length scales. Nat\nMater. 2006;5:439\u201351.","journal-title":"Nat Mater"},{"key":"287_CR38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tibtech.2015.11.004","volume":"34","author":"AB Hill","year":"2016","unstructured":"Hill AB, Chen M, Chen CK, Pfeifer BA, Jones CH. Overcoming\ngene-delivery hurdles: physiological considerations for nonviral vectors. Trends\nBiotechnol. 2016;34:91\u2013105.","journal-title":"Trends Biotechnol"},{"key":"287_CR39","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.4049\/jimmunol.165.5.2886","volume":"165","author":"TS Griffith","year":"2000","unstructured":"Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL.\nAdenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand\/Apo-2\nligand gene induces tumor cell apoptosis. J Immunol.\n2000;165:2886\u201394.","journal-title":"J Immunol"},{"key":"287_CR40","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/gt.2017.86","volume":"25","author":"A Galal El-Shemi","year":"2018","unstructured":"Galal El-Shemi A, Mohammed Ashshi A, Oh E, Jung BK, Basalamah M,\nAlsaegh A, et al. Efficacy of combining ING4 and TRAIL genes in cancer-targeting\ngene virotherapy strategy: first evidence in preclinical hepatocellular\ncarcinoma. Gene Ther. 2018;25:54\u201365.","journal-title":"Gene Ther"},{"key":"287_CR41","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","volume":"15","author":"H Yin","year":"2014","unstructured":"Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG.\nNon-viral vectors for gene-based therapy. Nat Rev Genet.\n2014;15:541\u201355.","journal-title":"Nat Rev Genet"},{"key":"287_CR42","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrd1775","volume":"4","author":"DW Pack","year":"2005","unstructured":"Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of\npolymers for gene delivery. Nat Rev Drug Discov.\n2005;4:581\u201393.","journal-title":"Nat Rev Drug Discov"},{"key":"287_CR43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1021\/cr800409e","volume":"109","author":"MA Mintzer","year":"2009","unstructured":"Mintzer MA, Simanek EE. Nonviral vectors for gene delivery. Chem\nRev. 2009;109:259\u2013302.","journal-title":"Chem Rev"},{"key":"287_CR44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/jps.10286","volume":"92","author":"CM Wiethoff","year":"2003","unstructured":"Wiethoff CM, Middaugh CR. Barriers to nonviral gene delivery. J\nPharm Sci. 2003;92:203\u201317.","journal-title":"J Pharm Sci"},{"key":"287_CR45","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1016\/j.biomaterials.2008.04.036","volume":"29","author":"M Morille","year":"2008","unstructured":"Morille M, Passirani C, Vonarbourg A, Clavreul A, Benoit JP.\nProgress in developing cationic vectors for non-viral systemic gene therapy\nagainst cancer. Biomaterials. 2008;29:3477\u201396.","journal-title":"Biomaterials"},{"key":"287_CR46","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.1073\/pnas.92.16.7297","volume":"92","author":"O Boussif","year":"1995","unstructured":"Boussif O, Lezoualc\u2019h F, Zanta MA, Mergny MD, Scherman D, Demeneix\nB, et al. A versatile vector for gene and oligonucleotide transfer into cells in\nculture and in vivo: polyethylenimine. Proc Natl Acad Sci USA.\n1995;92:7297\u2013301.","journal-title":"Proc Natl Acad Sci USA"},{"key":"287_CR47","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2006.04.014","volume":"114","author":"H Lv","year":"2006","unstructured":"Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids\nand cationic polymers in gene delivery. J Control Release.\n2006;114:100\u20139.","journal-title":"J Control Release"},{"key":"287_CR48","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jconrel.2018.07.047","volume":"286","author":"H Jiang","year":"2018","unstructured":"Jiang H, Wang S, Zhou X, Wang L, Ye L, Zhou Z, et al. New path to\ntreating pancreatic cancer: TRAIL gene delivery targeting the\nfibroblast-enriched tumor microenvironment. J Control Release.\n2018;286:254\u201363.","journal-title":"J Control Release"},{"key":"287_CR49","doi-asserted-by":"crossref","first-page":"435101","DOI":"10.1088\/0957-4484\/22\/43\/435101","volume":"22","author":"J Li","year":"2011","unstructured":"Li J, Gu B, Meng Q, Yan Z, Gao H, Chen X, et al. The use of\nmyristic acid as a ligand of polyethylenimine\/DNA nanoparticles for targeted\ngene therapy of glioblastoma. Nanotechnology. 2011;22:435101.","journal-title":"Nanotechnology"},{"key":"287_CR50","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1039\/C7PY00882A","volume":"8","author":"ZZ Pan","year":"2017","unstructured":"Pan ZZ, Kang XJ, Zeng YE, Zhang WY, Peng HG, Wang JY, et al. A\nmannosylated PEI-CPP hybrid for TRAIL gene targeting delivery for colorectal\ncancer therapy. Polym Chem. 2017;8:5275\u201385.","journal-title":"Polym Chem"},{"key":"287_CR51","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1039\/C6TB02990F","volume":"5","author":"J Tan","year":"2017","unstructured":"Tan J, Wang HY, Xu F, Chen YZ, Zhang M, Peng HG, et al.\nPoly-gamma-glutamic acid-based GGT-targeting and surface camouflage strategy for\nimproving cervical cancer gene therapy. J Mater Chem B.\n2017;5:1315\u201327.","journal-title":"J Mater Chem B"},{"key":"287_CR52","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1080\/10717544.2017.1406558","volume":"24","author":"S Wang","year":"2017","unstructured":"Wang S, Shao M, Zhong Z, Wang A, Cao J, Lu Y, et al. Co-delivery of\ngambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA\nnanoparticles for the treatment of triple negative breast cancer. Drug Deliv.\n2017;24:1791\u2013800.","journal-title":"Drug Deliv"},{"key":"287_CR53","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/nmat3187","volume":"11","author":"J Zhou","year":"2011","unstructured":"Zhou J, Liu J, Cheng CJ, Patel TR, Weller CE, Piepmeier JM, et al.\nBiodegradable poly(amine-co-ester) terpolymers for targeted gene delivery. Nat\nMater. 2011;11:82\u201390.","journal-title":"Nat Mater"},{"key":"287_CR54","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.7150\/thno.30302","volume":"9","author":"WY Zhang","year":"2019","unstructured":"Zhang WY, Kang XJ, Yuan B, Wang HY, Zhang T, Shi MJ, et al.\nNano-structural effects on gene transfection: large, botryoid-shaped\nnanoparticles enhance DNA delivery via macropinocytosis and effective\ndissociation. Theranostics. 2019;9:1580\u201398.","journal-title":"Theranostics"},{"key":"287_CR55","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/btm2.10019","volume":"1","author":"SY Tzeng","year":"2016","unstructured":"Tzeng SY, Wilson DR, Hansen SK, Quinones-Hinojosa A, Green JJ.\nPolymeric nanoparticle-based delivery of TRAIL DNA for cancer-specific killing.\nBioeng Transl Med. 2016;1:149\u201359.","journal-title":"Bioeng Transl Med"},{"key":"287_CR56","doi-asserted-by":"crossref","first-page":"10613","DOI":"10.1002\/adma.201603095","volume":"28","author":"N Qiu","year":"2016","unstructured":"Qiu N, Liu X, Zhong Y, Zhou Z, Piao Y, Miao L, et al.\nEsterase-activated charge-reversal polymer for fibroblast-exempt cancer gene\ntherapy. Adv Mater. 2016;28:10613\u201322.","journal-title":"Adv Mater"},{"key":"287_CR57","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1021\/acs.biomac.8b00440","volume":"19","author":"NS Qiu","year":"2018","unstructured":"Qiu NS, Gao JQ, Liu Q, Wang JQ, Shen YQ. Enzyme-responsive\ncharge-reversal polymer-mediated effective gene therapy for intraperitoneal\ntumors. Biomacromolecules. 2018;19:2308\u201319.","journal-title":"Biomacromolecules"},{"key":"287_CR58","doi-asserted-by":"crossref","first-page":"14196","DOI":"10.1021\/am503483w","volume":"6","author":"Z Chen","year":"2014","unstructured":"Chen Z, Zhang L, He Y, Li Y. Sandwich-type Au-PEI\/DNA\/PEI-Dexa\nnanocomplex for nucleus-targeted gene delivery in vitro and in vivo. ACS Appl\nMater Interfaces. 2014;6:14196\u2013206.","journal-title":"ACS Appl Mater Interfaces"},{"key":"287_CR59","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/adhm.201500563","volume":"4","author":"K Wang","year":"2015","unstructured":"Wang K, Kievit FM, Jeon M, Silber JR, Ellenbogen RG, Zhang M.\nNanoparticle-mediated target delivery of TRAIL as gene therapy for glioblastoma.\nAdv Health Mater. 2015;4:2719\u201326.","journal-title":"Adv Health Mater"},{"key":"287_CR60","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.nano.2012.04.006","volume":"9","author":"L Miao","year":"2013","unstructured":"Miao L, Zhang K, Qiao C, Jin X, Zheng C, Yang B, et al. Antitumor\neffect of human TRAIL on adenoid cystic carcinoma using magnetic\nnanoparticle-mediated gene expression. Nanomedicine.\n2013;9:141\u201350.","journal-title":"Nanomedicine"},{"key":"287_CR61","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/pola.10301","volume":"40","author":"DA Tomalia","year":"2002","unstructured":"Tomalia DA, Frechet JMJ. Discovery of dendrimers and dendritic\npolymers: a brief historical perspective. J Polym Sci Pol Chem.\n2002;40:2719\u201328.","journal-title":"J Polym Sci Pol Chem"},{"key":"287_CR62","doi-asserted-by":"crossref","first-page":"6832","DOI":"10.1016\/j.biomaterials.2011.05.064","volume":"32","author":"S Huang","year":"2011","unstructured":"Huang S, Li J, Han L, Liu S, Ma H, Huang R, et al. Dual targeting\neffect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma.\nBiomaterials. 2011;32:6832\u20138.","journal-title":"Biomaterials"},{"key":"287_CR63","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2217\/nnm.13.25","volume":"9","author":"M Al Robaian","year":"2014","unstructured":"Al Robaian M, Chiam KY, Blatchford DR, Dufes C. Therapeutic\nefficacy of intravenously administered transferrin-conjugated dendriplexes on\nprostate carcinomas. Nanomedicine. 2014;9:421\u201334.","journal-title":"Nanomedicine"},{"key":"287_CR64","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/10717544.2018.1440666","volume":"25","author":"N Altwaijry","year":"2018","unstructured":"Altwaijry N, Somani S, Parkinson JA, Tate RJ, Keating P, Warzecha\nM, et al. Regression of prostate tumors after intravenous administration of\nlactoferrin-bearing polypropylenimine dendriplexes encoding TNF-alpha, TRAIL,\nand interleukin-12. Drug Deliv. 2018;25:679\u201389.","journal-title":"Drug Deliv"},{"key":"287_CR65","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1021\/acs.biomac.8b00246","volume":"19","author":"H Wang","year":"2018","unstructured":"Wang H, Miao W, Wang F, Cheng Y. A self-assembled coumarin-anchored\ndendrimer for efficient gene delivery and light-responsive drug delivery.\nBiomacromolecules. 2018;19:2194\u2013201.","journal-title":"Biomacromolecules"},{"key":"287_CR66","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.actbio.2015.01.007","volume":"17","author":"Y Wang","year":"2015","unstructured":"Wang Y, Li L, Shao N, Hu Z, Chen H, Xu L, et al. Triazine-modified\ndendrimer for efficient TRAIL gene therapy in osteosarcoma. Acta Biomater.\n2015;17:115\u201324.","journal-title":"Acta Biomater"},{"key":"287_CR67","doi-asserted-by":"crossref","first-page":"S503","DOI":"10.1080\/21691401.2018.1500372","volume":"46","author":"E Pishavar","year":"2018","unstructured":"Pishavar E, Attaranzadeh A, Alibolandi M, Ramezani M, Hashemi M.\nModified PAMAM vehicles for effective TRAIL gene delivery to colon\nadenocarcinoma: in vitro and in vivo evaluation. Artif Cells Nanomed Biotechnol.\n2018;46:S503\u2013S13.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"287_CR68","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1208\/aapsj0901003","volume":"9","author":"ME Martin","year":"2007","unstructured":"Martin ME, Rice KG. Peptide-guided gene delivery. AAPS J.\n2007;9:E18\u2013E29.","journal-title":"AAPS J"},{"key":"287_CR69","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1021\/mp800251x","volume":"6","author":"SS Mangipudi","year":"2009","unstructured":"Mangipudi SS, Canine BF, Wang Y, Hatefi A. Development of a\ngenetically engineered biomimetic vector for targeted gene transfer to breast\ncancer cells. Mol Pharmacol. 2009;6:1100\u20139.","journal-title":"Mol Pharm"},{"key":"287_CR70","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1158\/0008-5472.CAN-11-3634","volume":"72","author":"A Kawabata","year":"2012","unstructured":"Kawabata A, Baoum A, Ohta N, Jacquez S, Seo GM, Berkland C, et al.\nIntratracheal administration of a nanoparticle-based therapy with the\nangiotensin II type 2 receptor gene attenuates lung cancer growth. Cancer Res.\n2012;72:2057\u201367.","journal-title":"Cancer Res"},{"key":"287_CR71","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/1061186X.2017.1289536","volume":"25","author":"FZ El Sharkawi","year":"2017","unstructured":"El Sharkawi FZ, Ewais SM, Fahmy RH, Rashed LA. PTEN and TRAIL genes\nloaded zein nanoparticles as potential therapy for hepatocellular carcinoma. J\nDrug Target. 2017;25:513\u201322.","journal-title":"J Drug Target"},{"key":"287_CR72","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2217\/nnm.10.80","volume":"5","author":"M Donkuru","year":"2010","unstructured":"Donkuru M, Badea I, Wettig S, Verrall R, Elsabahy M, Foldvari M.\nAdvancing nonviral gene delivery: lipid- and surfactant-based nanoparticle\ndesign strategies. Nanomedicine. 2010;5:1103\u201327.","journal-title":"Nanomedicine"},{"key":"287_CR73","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.biomaterials.2016.06.030","volume":"102","author":"C Luo","year":"2016","unstructured":"Luo C, Miao L, Zhao Y, Musetti S, Wang Y, Shi K, et al. A novel\ncationic lipid with intrinsic antitumor activity to facilitate gene therapy of\nTRAIL DNA. Biomaterials. 2016;102:239\u201348.","journal-title":"Biomaterials"},{"key":"287_CR74","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1158\/0008-5472.CAN-16-0866","volume":"77","author":"L Miao","year":"2017","unstructured":"Miao L, Liu Q, Lin CM, Luo C, Wang Y, Liu L, et al. Targeting\ntumor-associated fibroblasts for therapeutic delivery in desmoplastic tumors.\nCancer Res. 2017;77:719\u201331.","journal-title":"Cancer Res"},{"key":"287_CR75","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/hep.29513","volume":"67","author":"CH Liu","year":"2018","unstructured":"Liu CH, Chern GJ, Hsu FF, Huang KW, Sung YC, Huang HC, et al. A\nmultifunctional nanocarrier for efficient TRAIL-based gene therapy against\nhepatocellular carcinoma with desmoplasia in mice. Hepatology.\n2018;67:899\u2013913.","journal-title":"Hepatology"},{"key":"287_CR76","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.biomaterials.2016.09.019","volume":"111","author":"L Li","year":"2016","unstructured":"Li L, Song L, Yang X, Li X, Wu Y, He T, et al. Multifunctional\n\u201ccore-shell\u201d nanoparticles-based gene delivery for treatment of aggressive\nmelanoma. Biomaterials. 2016;111:124\u201337.","journal-title":"Biomaterials"},{"key":"287_CR77","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.7150\/thno.17588","volume":"7","author":"L Li","year":"2017","unstructured":"Li L, Li X, Wu Y, Song L, Yang X, He T, et al. Multifunctional\nnucleus-targeting nanoparticles with ultra-high gene transfection efficiency for\nin vivo gene therapy. Theranostics. 2017;7:1633\u201349.","journal-title":"Theranostics"},{"key":"287_CR78","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F,\nKrause D, et al. Minimal criteria for defining multipotent mesenchymal stromal\ncells. Cytotherapy. 2006;8:315\u20137.","journal-title":"Cytotherapy"},{"key":"287_CR79","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1089\/scd.2010.0140","volume":"19","author":"F Mosna","year":"2010","unstructured":"Mosna F, Sensebe L, Krampera M. Human bone marrow and adipose\ntissue mesenchymal stem cells: a user\u2019s guide. Stem Cells Dev.\n2010;19:1449\u201370.","journal-title":"Stem Cells Dev"},{"key":"287_CR80","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-015-0426-0","volume":"13","author":"N D\u2019Souza","year":"2015","unstructured":"D\u2019Souza N, Rossignoli F, Golinelli G, Grisendi G, Spano C, Candini\nO, et al. Mesenchymal stem\/stromal cells as a delivery platform in cell and gene\ntherapies. BMC Med. 2015;13:186.","journal-title":"BMC Med"},{"key":"287_CR81","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/14653240802618085","volume":"10","author":"EM Horwitz","year":"2008","unstructured":"Horwitz EM, Dominici M. How do mesenchymal stromal cells exert\ntheir therapeutic benefit? Cytotherapy. 2008;10:771\u20134.","journal-title":"Cytotherapy"},{"key":"287_CR82","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1089\/scd.2015.0008","volume":"24","author":"H Munir","year":"2015","unstructured":"Munir H, McGettrick HM. Mesenchymal stem cell therapy for\nautoimmune disease: risks and rewards. Stem Cells Dev.\n2015;24:2091\u2013100.","journal-title":"Stem Cells Dev"},{"key":"287_CR83","first-page":"787","volume":"1","author":"G Grisendi","year":"2011","unstructured":"Grisendi G, Bussolari R, Veronesi E, Piccinno S, Burns JS, De\nSantis G, et al. Understanding tumor-stroma interplays for targeted therapies by\narmed mesenchymal stromal progenitors: the Mesenkillers. Am J Cancer Res.\n2011;1:787\u2013805.","journal-title":"Am J Cancer Res"},{"key":"287_CR84","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1158\/0008-5472.CAN-09-1865","volume":"70","author":"G Grisendi","year":"2010","unstructured":"Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V, Veronesi\nE, et al. Adipose-derived mesenchymal stem cells as stable source of tumor\nnecrosis factor-related apoptosis-inducing ligand delivery for cancer therapy.\nCancer Res. 2010;70:3718\u201329.","journal-title":"Cancer Res"},{"key":"287_CR85","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1002\/ijc.30402","volume":"139","author":"R Guiho","year":"2016","unstructured":"Guiho R, Biteau K, Grisendi G, Taurelle J, Chatelais M, Gantier M,\net al. TRAIL delivered by mesenchymal stromal\/stem cells counteracts tumor\ndevelopment in orthotopic Ewing sarcoma models. Int J Cancer.\n2016;139:2802\u201311.","journal-title":"Int J Cancer"},{"key":"287_CR86","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.biomaterials.2015.11.023","volume":"81","author":"PT Yin","year":"2016","unstructured":"Yin PT, Shah S, Pasquale NJ, Garbuzenko OB, Minko T, Lee KB. Stem\ncell-based gene therapy activated using magnetic hyperthermia to enhance the\ntreatment of cancer. Biomaterials. 2016;81:46\u201357.","journal-title":"Biomaterials"},{"key":"287_CR87","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1158\/0008-5472.CAN-08-4698","volume":"69","author":"MR Loebinger","year":"2009","unstructured":"Loebinger MR, Eddaoudi A, Davies D, Janes SM. Mesenchymal stem cell\ndelivery of TRAIL can eliminate metastatic cancer. Cancer Res.\n2009;69:4134\u201342.","journal-title":"Cancer Res"},{"key":"287_CR88","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1021\/mp300254s","volume":"9","author":"YL Hu","year":"2012","unstructured":"Hu YL, Huang B, Zhang TY, Miao PH, Tang GP, Tabata Y, et al.\nMesenchymal stem cells as a novel carrier for targeted delivery of gene in\ncancer therapy based on nonviral transfection. Mol Pharmacol.\n2012;9:2698\u2013709.","journal-title":"Mol Pharm"},{"key":"287_CR89","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1016\/j.biomaterials.2013.12.037","volume":"35","author":"C Yan","year":"2014","unstructured":"Yan C, Yang M, Li Z, Li S, Hu X, Fan D, et al. Suppression of\northotopically implanted hepatocarcinoma in mice by umbilical cord-derived\nmesenchymal stem cells with sTRAIL gene expression driven by AFP promoter.\nBiomaterials. 2014;35:3035\u201343.","journal-title":"Biomaterials"},{"key":"287_CR90","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/stem.433","volume":"28","author":"CA Ramos","year":"2010","unstructured":"Ramos CA, Asgari Z, Liu E, Yvon E, Heslop HE, Rooney CM, et al. An\ninducible caspase 9 suicide gene to improve the safety of mesenchymal stromal\ncell therapies. Stem Cells. 2010;28:1107\u201315.","journal-title":"Stem Cells"},{"key":"287_CR91","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41417-018-0034-1","volume":"26","author":"F Rossignoli","year":"2019","unstructured":"Rossignoli F, Grisendi G, Spano C, Golinelli G, Recchia A, Rovesti\nG, et al. Inducible Caspase9-mediated suicide gene for MSC-based cancer gene\ntherapy. Cancer Gene Ther. 2019;26:11\u20136.","journal-title":"Cancer Gene Ther"},{"key":"287_CR92","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","volume":"105","author":"KC Straathof","year":"2005","unstructured":"Straathof KC, Pule MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, et\nal. An inducible caspase 9 safety switch for T-cell therapy. Blood.\n2005;105:4247\u201354.","journal-title":"Blood"},{"key":"287_CR93","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.actbio.2018.09.015","volume":"80","author":"YS Malik","year":"2018","unstructured":"Malik YS, Sheikh MA, Xing Z, Guo Z, Zhu X, Tian H, et al.\nPolylysine-modified polyethylenimine polymer can generate genetically engineered\nmesenchymal stem cells for combinational suicidal gene therapy in glioblastoma.\nActa Biomater. 2018;80:144\u201353.","journal-title":"Acta Biomater"},{"key":"287_CR94","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.biomaterials.2018.08.024","volume":"182","author":"J Han","year":"2018","unstructured":"Han J, Hwang HS, Na K. TRAIL-secreting human mesenchymal stem cells\nengineered by a non-viral vector and photochemical internalization for\npancreatic cancer gene therapy. Biomaterials. 2018;182:259\u201368.","journal-title":"Biomaterials"},{"key":"287_CR95","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","volume":"100","author":"DG Gilliland","year":"2002","unstructured":"Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and\nleukemia. Blood. 2002;100:1532\u201342.","journal-title":"Blood"},{"key":"287_CR96","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.canlet.2011.10.010","volume":"315","author":"NF Sun","year":"2012","unstructured":"Sun NF, Meng QY, Tian AL, Hu SY, Wang RH, Liu ZX, et al.\nNanoliposome-mediated FL\/TRAIL double-gene therapy for colon cancer: in vitro\nand in vivo evaluation. Cancer Lett. 2012;315:69\u201377.","journal-title":"Cancer Lett"},{"key":"287_CR97","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1038\/sj.onc.1203936","volume":"19","author":"S Hinz","year":"2000","unstructured":"Hinz S, Trauzold A, Boenicke L, Sandberg C, Beckmann S, Bayer E, et\nal. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and\nTRAIL-receptor-mediated apoptosis. Oncogene. 2000;19:5477\u201386.","journal-title":"Oncogene"},{"key":"287_CR98","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.1038\/sj.onc.1204750","volume":"20","author":"S Fulda","year":"2001","unstructured":"Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B,\nDebatin KM. Sensitization for death receptor- or drug-induced apoptosis by\nre-expression of caspase-8 through demethylation or gene transfer. Oncogene.\n2001;20:5865\u201377.","journal-title":"Oncogene"},{"key":"287_CR99","first-page":"1314","volume":"61","author":"A Eggert","year":"2001","unstructured":"Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ho R, Ikegaki N, et\nal. Resistance to tumor necrosis factor-related apoptosis-inducing ligand\n(TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of\ncaspase-8 expression. Cancer Res. 2001;61:1314\u20139.","journal-title":"Cancer Res"},{"key":"287_CR100","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/sj.gt.3301797","volume":"9","author":"L Zhang","year":"2002","unstructured":"Zhang L, Gu J, Lin T, Huang X, Roth JA, Fang B. Mechanisms involved\nin development of resistance to adenovirus-mediated proapoptotic gene therapy in\nDLD1 human colon cancer cell line. Gene Ther. 2002;9:1262\u201370.","journal-title":"Gene Ther"},{"key":"287_CR101","first-page":"335","volume":"6","author":"K Kim","year":"2000","unstructured":"Kim K, Fisher MJ, Xu SQ, el-Deiry WS. Molecular determinants of\nresponse to TRAIL in killing of normal and cancer cells. Clin Cancer Res.\n2000;6:335\u201346.","journal-title":"Clin Cancer Res"},{"key":"287_CR102","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/91000","volume":"7","author":"K Ichikawa","year":"2001","unstructured":"Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, et al.\nTumoricidal activity of a novel anti-human DR5 monoclonal antibody without\nhepatocyte cytotoxicity. Nat Med. 2001;7:954\u201360.","journal-title":"Nat Med"},{"key":"287_CR103","doi-asserted-by":"crossref","first-page":"8247","DOI":"10.1128\/MCB.21.24.8247-8254.2001","volume":"21","author":"A Krueger","year":"2001","unstructured":"Krueger A, Baumann S, Krammer PH, Kirchhoff S. FLICE-inhibitory\nproteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol.\n2001;21:8247\u201354.","journal-title":"Mol Cell Biol"},{"key":"287_CR104","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1097\/01.LAB.0000079328.76631.28","volume":"83","author":"H Okano","year":"2003","unstructured":"Okano H, Shiraki K, Inoue H, Kawakita T, Yamanaka T, Deguchi M, et\nal. Cellular FLICE\/caspase-8-inhibitory protein as a principal regulator of cell\ndeath and survival in human hepatocellular carcinoma. Lab Invest.\n2003;83:1033\u201343.","journal-title":"Lab Invest"},{"key":"287_CR105","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1182\/blood.V94.5.1727","volume":"94","author":"CG Tepper","year":"1999","unstructured":"Tepper CG, Seldin MF. Modulation of caspase-8 and FLICE-inhibitory\nprotein expression as a potential mechanism of Epstein-Barr virus tumorigenesis\nin Burkitt\u2019s lymphoma. Blood. 1999;94:1727\u201337.","journal-title":"Blood"},{"key":"287_CR106","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0092-8674(00)80085-9","volume":"86","author":"X Liu","year":"1996","unstructured":"Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic\nprogram in cell-free extracts: requirement for dATP and cytochrome c. Cell. 1996;86:147\u201357.","journal-title":"Cell"},{"key":"287_CR107","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1126\/science.275.5303.1132","volume":"275","author":"RM Kluck","year":"1997","unstructured":"Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of\ncytochrome c from mitochondria: a primary\nsite for Bcl-2 regulation of apoptosis. Science.\n1997;275:1132\u20136.","journal-title":"Science"},{"key":"287_CR108","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/pros.10155","volume":"53","author":"CP Ng","year":"2002","unstructured":"Ng CP, Zisman A, Bonavida B. Synergy is achieved by complementation\nwith Apo2L\/TRAIL and actinomycin D in Apo2L\/TRAIL-mediated apoptosis of prostate\ncancer cells: role of XIAP in resistance. Prostate.\n2002;53:286\u201399.","journal-title":"Prostate"},{"key":"287_CR109","first-page":"1051","volume":"1","author":"CP Ng","year":"2002","unstructured":"Ng CP, Bonavida B. X-linked inhibitor of apoptosis (XIAP) blocks\nApo2 ligand\/tumor necrosis factor-related apoptosis-inducing ligand-mediated\napoptosis of prostate cancer cells in the presence of mitochondrial activation:\nsensitization by overexpression of second mitochondria-derived activator of\ncaspase\/direct IAP-binding protein with low pl (Smac\/DIABLO). Mol Cancer Ther.\n2002;1:1051\u20138.","journal-title":"Mol Cancer Ther"},{"key":"287_CR110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0092-8674(00)00008-8","volume":"102","author":"C Du","year":"2000","unstructured":"Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein\nthat promotes cytochrome c-dependent caspase\nactivation by eliminating IAP inhibition. Cell.\n2000;102:33\u201342.","journal-title":"Cell"},{"key":"287_CR111","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0092-8674(00)00009-X","volume":"102","author":"AM Verhagen","year":"2000","unstructured":"Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, et\nal. Identification of DIABLO, a mammalian protein that promotes apoptosis by\nbinding to and antagonizing IAP proteins. Cell.\n2000;102:43\u201353.","journal-title":"Cell"},{"key":"287_CR112","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/sj.cgt.7700792","volume":"12","author":"L Zhang","year":"2005","unstructured":"Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced\napoptosis in cancer. Cancer Gene Ther. 2005;12:228\u201337.","journal-title":"Cancer Gene Ther"},{"key":"287_CR113","first-page":"6401","volume":"9","author":"C Pingoud-Meier","year":"2003","unstructured":"Pingoud-Meier C, Lang D, Janss AJ, Rorke LB, Phillips PC, Shalaby\nT, et al. Loss of caspase-8 protein expression correlates with unfavorable\nsurvival outcome in childhood medulloblastoma. Clin Cancer Res.\n2003;9:6401\u20139.","journal-title":"Clin Cancer Res"},{"key":"287_CR114","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/carcin\/bgt137","volume":"34","author":"MJ Yoon","year":"2013","unstructured":"Yoon MJ, Kang YJ, Kim IY, Kim EH, Lee JA, Lim JH, et al. Monensin,\na polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via\nendoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation.\nCarcinogenesis. 2013;34:1918\u201328.","journal-title":"Carcinogenesis"},{"key":"287_CR115","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.biomaterials.2017.12.018","volume":"158","author":"F Xu","year":"2018","unstructured":"Xu F, Zhong H, Chang Y, Li D, Jin H, Zhang M, et al. Targeting\ndeath receptors for drug-resistant cancer therapy: Codelivery of pTRAIL and\nmonensin using dual-targeting and stimuli-responsive self-assembling\nnanocomposites. Biomaterials. 2018;158:56\u201373.","journal-title":"Biomaterials"},{"key":"287_CR116","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0083-6729(04)67019-1","volume":"67","author":"XX Wu","year":"2004","unstructured":"Wu XX, Ogawa O, Kakehi Y. TRAIL and chemotherapeutic drugs in\ncancer therapy. Vitam Horm. 2004;67:365\u201383.","journal-title":"Vitam Horm"},{"key":"287_CR117","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1208\/s12249-017-0913-z","volume":"19","author":"M Ebrahimian","year":"2018","unstructured":"Ebrahimian M, Taghavi S, Ghoreishi M, Sedghi S, Amel Farzad S,\nRamezani M, et al. Evaluation of efficiency of modified polypropylenimine (PPI)\nwith alkyl chains as non-viral vectors used in co-delivery of doxorubicin and\nTRAIL plasmid. AAPS PharmSciTech. 2018;19:1029\u201336.","journal-title":"AAPS PharmSciTech"},{"key":"287_CR118","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.biomaterials.2011.10.043","volume":"33","author":"H Fan","year":"2012","unstructured":"Fan H, Hu QD, Xu FJ, Liang WQ, Tang GP, Yang WT. In vivo treatment\nof tumors using host-guest conjugated nanoparticles functionalized with\ndoxorubicin and therapeutic gene pTRAIL. Biomaterials.\n2012;33:1428\u201336.","journal-title":"Biomaterials"},{"key":"287_CR119","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.biomaterials.2010.09.070","volume":"32","author":"L Han","year":"2011","unstructured":"Han L, Huang R, Li J, Liu S, Huang S, Jiang C. Plasmid pORF-hTRAIL\nand doxorubicin co-delivery targeting to tumor using peptide-conjugated\npolyamidoamine dendrimer. Biomaterials. 2011;32:1242\u201352.","journal-title":"Biomaterials"},{"key":"287_CR120","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1016\/j.biomaterials.2012.03.031","volume":"33","author":"S Liu","year":"2012","unstructured":"Liu S, Guo Y, Huang R, Li J, Huang S, Kuang Y, et al. Gene and\ndoxorubicin co-delivery system for targeting therapy of glioma. Biomaterials.\n2012;33:4907\u201316.","journal-title":"Biomaterials"},{"key":"287_CR121","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1002\/adma.201101899","volume":"23","author":"J Li","year":"2011","unstructured":"Li J, Zhou L, Ye D, Huang S, Shao K, Huang R, et al.\nCholine-derivate-modified nanoparticles for brain-targeting gene delivery. Adv\nMater. 2011;23:4516\u201320.","journal-title":"Adv Mater"},{"key":"287_CR122","doi-asserted-by":"crossref","first-page":"9142","DOI":"10.1016\/j.biomaterials.2013.08.030","volume":"34","author":"J Li","year":"2013","unstructured":"Li J, Guo Y, Kuang Y, An S, Ma H, Jiang C. Choline\ntransporter-targeting and co-delivery system for glioma therapy. Biomaterials.\n2013;34:9142\u20138.","journal-title":"Biomaterials"},{"key":"287_CR123","first-page":"916","volume":"33","author":"X Sun","year":"2012","unstructured":"Sun X, Pang Z, Ye H, Qiu B, Guo L, Li J, et al. Co-delivery of\npEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated\nliposome. Biomaterials. 2012;33:916\u201324.","journal-title":"Biomaterials"},{"key":"287_CR124","doi-asserted-by":"crossref","first-page":"17811","DOI":"10.1074\/jbc.M111152200","volume":"277","author":"S Nirthanan","year":"2002","unstructured":"Nirthanan S, Charpantier E, Gopalakrishnakone P, Gwee MC, Khoo HE,\nCheah LS, et al. Candoxin, a novel toxin from Bungarus candidus, is a reversible\nantagonist of muscle (alphabetagammadelta) but a poorly reversible antagonist of\nneuronal alpha 7 nicotinic acetylcholine receptors. J Biol Chem.\n2002;277:17811\u201320.","journal-title":"J Biol Chem"},{"key":"287_CR125","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jconrel.2012.02.022","volume":"160","author":"C Zhan","year":"2012","unstructured":"Zhan C, Wei X, Qian J, Feng L, Zhu J, Lu W. Co-delivery of TRAIL\ngene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo. J\nControl Release. 2012;160:630\u20136.","journal-title":"J Control Release"},{"key":"287_CR126","doi-asserted-by":"crossref","first-page":"436","DOI":"10.7150\/thno.27576","volume":"9","author":"F Rossignoli","year":"2019","unstructured":"Rossignoli F, Spano C, Grisendi G, Foppiani EM, Golinelli G,\nMastrolia I, et al. MSC-delivered soluble TRAIL and paclitaxel as novel\ncombinatory treatment for pancreatic adenocarcinoma. Theranostics.\n2019;9:436\u201348.","journal-title":"Theranostics"},{"key":"287_CR127","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3892\/ol.2012.926","volume":"4","author":"F Li","year":"2012","unstructured":"Li F, Guo Y, Han L, Duan Y, Fang F, Niu S, et al. In vitro and in\nvivo growth inhibition of drug-resistant ovarian carcinoma cells using a\ncombination of cisplatin and a TRAIL-encoding retrovirus. Oncol Lett.\n2012;4:1254\u20138.","journal-title":"Oncol Lett"},{"key":"287_CR128","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10495-009-0321-2","volume":"14","author":"T Newsom-Davis","year":"2009","unstructured":"Newsom-Davis T, Prieske S, Walczak H. Is TRAIL the holy grail of\ncancer therapy? Apoptosis. 2009;14:607\u201323.","journal-title":"Apoptosis"},{"key":"287_CR129","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1080\/1061186X.2018.1519028","volume":"27","author":"X Zhou","year":"2019","unstructured":"Zhou X, Liu Z, Wang H, Liu X, Zhou Z, Tang J, et al. SAHA\n(vorinostat) facilitates functional polymer-based gene transfection via\nupregulation of ROS and synergizes with TRAIL gene delivery for cancer therapy.\nJ Drug Target. 2019;27:306\u201314.","journal-title":"J Drug Target"},{"key":"287_CR130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.canlet.2018.10.012","volume":"442","author":"SA Choi","year":"2019","unstructured":"Choi SA, Lee C, Kwak PA, Park CK, Wang KC, Phi JH, et al. Histone\ndeacetylase inhibitor panobinostat potentiates the anti-cancer effects of\nmesenchymal stem cell-based sTRAIL gene therapy against malignant glioma. Cancer\nLett. 2019;442:161\u20139.","journal-title":"Cancer Lett"},{"key":"287_CR131","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.3892\/mmr.2017.6472","volume":"15","author":"Y Ge","year":"2017","unstructured":"Ge Y, Lei W, Ma Y, Wang Y, Wei B, Chen X, et al. Synergistic\nantitumor effects of CDK inhibitor SNS032 and an oncolytic adenovirus\ncoexpressing TRAIL and Smac in pancreatic cancer. Mol Med Rep.\n2017;15:3521\u20138.","journal-title":"Mol Med Rep"},{"key":"287_CR132","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.7150\/thno.19893","volume":"7","author":"S Ma","year":"2017","unstructured":"Ma S, Sun J, Guo Y, Zhang P, Liu Y, Zheng D, et al. Combination of\nAAV-TRAIL with miR-221-Zip therapeutic strategy overcomes the resistance to\nTRAIL induced apoptosis in liver cancer. Theranostics.\n2017;7:3228\u201342.","journal-title":"Theranostics"}],"updated-by":[{"DOI":"10.1038\/s41401-020-0444-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000}}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41401-019-0287-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-019-0287-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-019-0287-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:02:17Z","timestamp":1684616537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-019-0287-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,23]]},"references-count":132,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["287"],"URL":"https:\/\/doi.org\/10.1038\/s41401-019-0287-8","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41401-020-0444-0","asserted-by":"object"}]},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,23]]},"assertion":[{"value":"22 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41401-020-0444-0","URL":"https:\/\/doi.org\/10.1038\/s41401-020-0444-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}